Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Blood

• Publication date

  2013-04-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2012-08-452938PMID 23372164
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia

  2013influential reference
• ISCN 2013 : an international system for human cytogenetic nomenclature (2013) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature

  2013cited by this paper
• Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.

  2012cited by this paper
• Revised international prognostic scoring system for myelodysplastic syndromes.

  2012influential reference
• SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).

  2012cited by this paper
• Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

  2011cited by this paper
• Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)

  2011influential reference
• Frequent pathway mutations of splicing machinery in myelodysplasia

  2011cited by this paper
• Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

  2011influential reference
• Myelodysplastic/myeloproliferative neoplasms.

  2011cited by this paper
• Cytogenetic risk stratification in chronic myelomonocytic leukemia

  2011influential reference
• Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.

  2010cited by this paper
• Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

  2010influential reference
• Myelodysplastic/myeloproliferative neoplasms.

  2009cited by this paper
• The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features

  2008influential reference
• Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

  2008cited by this paper
• Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System

  2007influential reference
• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

  2007cited by this paper
• Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

  2007cited by this paper
• The International System

  2006cited by this paper
• Concordance probability and discriminatory power in proportional hazards regression

  2005influential reference
• Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

  2005influential reference
• E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues

  2002cited by this paper
• New prognostic parameters for chronic myelomonocytic leukemia.

  2002influential reference
• Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.

  2002influential reference
• Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center.

  2002influential reference
• Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia--distinct subgroups or two stages of the same disease?

  2001influential reference
• Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution.

  2001cited by this paper
• Problems in the classification of CMML--dysplastic versus proliferative type.

  1998influential reference
• International scoring system for evaluating prognosis in myelodysplastic syndromes.

  1997cited by this paper
• The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group

  1994cited by this paper
• Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival

  1988influential reference
• Proposals for the classification of the myelodysplastic syndromes

  1982cited by this paper
• An international system for human cytogenetic nomenclature

  1978cited by this paper
• Chronic Myelomonocytic Leukaemia

  1975cited by this paper

• Unveiling relative lymphopenia and elevated monocyte‐to‐lymphocyte count as novel independent adverse prognostic factors in chronic myelomonocytic leukemia (CMML)—Proposal of the objective prognostic index for CMML (OPIC)

  2026cites this paper
• Chronic myelomonocytic leukaemia

  2025cites this paper
• Decoding the immune microenvironment of secondary chronic myelomonocytic leukemia due to diffuse large B-cell lymphoma with CD19 CAR-T failure by single-cell RNA-sequencing

  2025cites this paper
• Clinical management of CMML—State of the art

  2025influential citation
• Myeloablative and Reduced Intensity Allogeneic Transplant in Patients with Myeloproliferative Neoplasms.

  2025cites this paper
• Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly

  2025cites this paper
• Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients

  2025cites this paper
• Chronic myelomonocytic leukemia (CMML): a genetically heterogeneous entity

  2025cites this paper
• Molecular taxonomy of MDS/CMML patients influences responses to hypomethylating agents and clinical outcomes.

  2025cites this paper
• Classification of Myelodysplastic, Myeloproliferative, and Myelodysplastic/Myeloproliferative Neoplasms: The Past, Present, and Future

  2025cites this paper
• Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes– a retrospective matched-pairs analysis

  2025cites this paper
• Integration of Optical Genome Mapping in the Cytogenomic and Molecular Work‐Up of Hematological Malignancies: Expert Recommendations From the International Consortium for Optical Genome Mapping

  2025cites this paper
• The incidence, risk factors, and survival of acute myeloid leukemia secondary to chronic myelomonocytic leukemia: a population-based study

  2025cites this paper
• Comparison of outcomes between haploidentical and matched related donors for chronic myelomonocytic leukemia: A multicenter real‐world study

  2025cites this paper
• Contemporary CMML Risk Stratification and Management

  2025cites this paper
• Dynamic Mortality Risk Prediction in Myelodysplastic Syndromes Using Longitudinal Clinical Data

  2025cites this paper
• Raw lacquer-associated familial chronic myelomonocytic leukemia with multi-hit TET2 mutations

  2025cites this paper
• MDS patient registries - achievements and challenges

  2024cites this paper
• A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study

  2024cites this paper
• Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management

  2024cites this paper
• Spontaneous remission of choroidal involvement by chronic myelomonocytic leukemia: a case report

  2024cites this paper
• Enhanced Survival of Chronic Myelomonocytic Leukemia-Dysplastic over Proliferative Subtype after Allogeneic Hematopoietic Cell Transplant: A Tertiary Center Experience and Literature Review

  2024cites this paper
• Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National Analysis.

  2024cites this paper
• 异基因造血干细胞移植治疗慢性粒-单核细胞白血病的临床结局

  2024cites this paper
• Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.

  2024cites this paper
• Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study

  2024cites this paper
• AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular

  2024cites this paper
• ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia

  2024cites this paper
• Myelodysplastic Syndrome: Clinical Characteristics and Significance of Preclinically Detecting Biallelic Mutations in the TET2 Gene

  2024cites this paper
• Survival Outcomes of U.S. Patients with CMML: A Two-Decade Analysis from the SEER Database

  2024cites this paper
• Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification

  2024cites this paper
• CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia

  2024cites this paper
• 单中心109例慢性粒-单核细胞白血病患者的分子学特征分析

  2023cites this paper
• Network-based clustering unveils interconnected landscapes of genomic and clinical features across myeloid malignancies

  2023cites this paper
• Increased Inflammasome Activation Is Associated with Aging and Chronic Myelomonocytic Leukemia Disease Severity.

  2023cites this paper
• Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms

  2023cites this paper
• Sex‐associated differences in genomic profile of chronic myelomonocytic leukemia involving differential representation of SRSF2 gene mutation

  2023cites this paper
• NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

  2023cites this paper
• Co-existing squamous cell carcinoma and chronic myelomonocytic leukemia with ASXL1 and EZH2 gene mutations: A case report

  2023cites this paper
• Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia

  2023cites this paper
• Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML

  2023influential citation
• Outcomes of intermediate or high‐risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience

  2023influential citation
• Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022

  2023cites this paper
• Non-hepatosplenic extramedullary manifestations in patients affected by Chronic myelomonocytic leukemia. Case report and meta-analysis of the published series

  2023cites this paper
• Advances in myelodysplastic/myeloproliferative neoplasms

  2022cites this paper
• Significance of C-reactive protein in patients with chronic myelomonocytic leukemia

  2022cites this paper
• Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia

  2022cites this paper
• Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component

  2022cites this paper
• Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia

  2022cites this paper
• Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm- overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement.

  2022cites this paper
• The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis

  2022cites this paper
• The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)

  2022influential citation
• Molecular assessment and the current limits of post-transplant prognostication for chronic myelomonocytic leukemia

  2022cites this paper
• Significance of reduced renal function in patients with chronic myelomonocytic leukemia

  2022influential citation
• How I diagnose and treat chronic myelomonocytic leukemia

  2022cites this paper
• The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19

  2022cites this paper
• Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia

  2022cites this paper
• Mutational landscape of chronic myelomonocytic leukemia in Chinese patients

  2022cites this paper
• Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)

  2022influential citation
• Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management

  2022cites this paper
• A retrospective study of cladribine and low‐dose cytarabine–based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia

  2022cites this paper
• Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network

  2022cites this paper
• Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes

  2022influential citation
• The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes

  2022cites this paper
• Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.

  2022cites this paper
• Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia

  2022influential citation
• Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD

  2022cites this paper
• International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.

  2022cites this paper
• Role of Allogeneic Transplantation In Chronic Myelomonocytic Leukemia: An International Collaborative Analysis.

  2022cites this paper
• Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum

  2022cites this paper
• Myeloid leukemoid reaction after initial azacitidine therapy for chronic myelomonocytic leukemia

  2022cites this paper
• SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity

  2022cites this paper
• Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders

  2022cites this paper
• Treatment Outcomes and Prognostic Factors in 66 Patients with Chronic Myelomonocytic Leukemia (CMML) in a Single Center

  2022cites this paper
• Chronic Myelomonocytic Leukemia (CMML): A systematic Review of Literature and Update

  2022cites this paper
• Heightened NLRP3 inflammasome activation is associated with aging and CMML diseases severity

  2022influential citation
• Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center.

  2021cites this paper
• Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia

  2021cites this paper
• Myelodysplastic syndromes and overlap syndromes

  2021cites this paper
• Diagnosis and treatment of chronic myelomonocytic leukemia

  2021influential citation
• Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis — Chronic Myelomonocytic Leukemia and Beyond

  2021cites this paper
• Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms

  2021cites this paper
• Classification of Monocytes, Promonocytes and Monoblasts Using Deep Neural Network Models: An Area of Unmet Need in Diagnostic Hematopathology

  2021cites this paper
• Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients

  2021influential citation
• Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/β‐catenin signalling by parallel RNA sequencing and dysfunctional phenotypes

  2021cites this paper
• Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview

  2021influential citation
• Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?

  2021cites this paper
• Contemporary risk stratification and treatment of chronic myelomonocytic leukemia.

  2021influential citation
• Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms

  2021cites this paper
• Chronic Myelomonocytic Leukemia: Hematopathology Perspective.

  2021influential citation
• A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation.

  2021cites this paper
• Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

  2021cites this paper
• Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches

  2021cites this paper
• Leucémie myélomonocytaire chronique

  2021cites this paper
• Pleural effusion in hematological pathology

  2021cites this paper
• Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: Clinical and molecular genetic prognostic factors in a Nordic population.

  2021cites this paper
• Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study

  2021cites this paper
• Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia

  2021cites this paper
• Real‐world data of chronic myelomonocytic leukemia: A chinese single‐center retrospective study

  2021cites this paper
• Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review

  2021cites this paper